Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKT NASDAQ:OKYO NASDAQ:PMN NYSEARCA:SBM NASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.62+3.2%$1.66$1.42▼$4.20$120.72M0.89178,182 shs92,503 shsOKYOOKYO Pharma$2.43+8.5%$2.23$0.90▼$3.35$84.25M-0.14167,495 shs184,567 shsPMNPromis Neurosciences$0.45+2.8%$0.49$0.38▼$1.59$23.55M-0.17878,298 shs589,299 shsSBMProShares Short Basic Materials$46.38$46.38$42.85▼$55.15$1.86M-1.13,024 shsN/AVRDNViridian Therapeutics$24.09-0.5%$19.83$9.90▼$27.20$1.98B0.49828,935 shs1.08 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics0.00%-2.48%-4.27%-16.49%-26.29%OKYOOKYO Pharma0.00%+14.87%+13.13%-20.57%+119.61%PMNPromis Neurosciences0.00%-10.69%-0.88%-60.93%-55.80%SBMProShares Short Basic Materials0.00%0.00%0.00%0.00%0.00%VRDNViridian Therapeutics0.00%+15.34%+24.60%+44.19%-3.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.62+3.2%$1.66$1.42▼$4.20$120.72M0.89178,182 shs92,503 shsOKYOOKYO Pharma$2.43+8.5%$2.23$0.90▼$3.35$84.25M-0.14167,495 shs184,567 shsPMNPromis Neurosciences$0.45+2.8%$0.49$0.38▼$1.59$23.55M-0.17878,298 shs589,299 shsSBMProShares Short Basic Materials$46.38$46.38$42.85▼$55.15$1.86M-1.13,024 shsN/AVRDNViridian Therapeutics$24.09-0.5%$19.83$9.90▼$27.20$1.98B0.49828,935 shs1.08 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics0.00%-2.48%-4.27%-16.49%-26.29%OKYOOKYO Pharma0.00%+14.87%+13.13%-20.57%+119.61%PMNPromis Neurosciences0.00%-10.69%-0.88%-60.93%-55.80%SBMProShares Short Basic Materials0.00%0.00%0.00%0.00%0.00%VRDNViridian Therapeutics0.00%+15.34%+24.60%+44.19%-3.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$8.00393.83% UpsideOKYOOKYO Pharma 2.00Hold$7.00188.07% UpsidePMNPromis Neurosciences 2.50Moderate Buy$4.33863.18% UpsideSBMProShares Short Basic Materials 0.00N/AN/AN/AVRDNViridian Therapeutics 2.70Moderate Buy$34.8844.77% UpsideCurrent Analyst Ratings BreakdownLatest VRDN, SBM, IKT, PMN, and OKYO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025OKYOOKYO PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PMNPromis NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025VRDNViridian TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025OKYOOKYO PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PMNPromis NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025VRDNViridian TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/23/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.009/16/2025OKYOOKYO PharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/25/2025VRDNViridian TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.008/7/2025VRDNViridian TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $30.008/7/2025VRDNViridian TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $41.00(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/APMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ASBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AN/AVRDNViridian Therapeutics$300K6,558.10N/AN/A$6.09 per share3.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AOKYOOKYO Pharma-$4.71MN/A0.00N/AN/AN/AN/AN/A12/22/2025 (Estimated)PMNPromis Neurosciences$2.78M-$0.21N/AN/AN/AN/A-266.69%-131.59%11/13/2025 (Estimated)SBMProShares Short Basic MaterialsN/AN/A0.00∞N/AN/AN/AN/AN/AVRDNViridian Therapeutics-$269.95M-$3.83N/AN/AN/A-112,806.88%-78.95%-49.91%11/11/2025 (Estimated)Latest VRDN, SBM, IKT, PMN, and OKYO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025PMNPromis Neurosciences-$0.15N/AN/AN/AN/AN/A11/11/2025Q3 2025VRDNViridian Therapeutics-$0.72N/AN/AN/A$16.21 millionN/A8/13/2025Q2 2025PMNPromis Neurosciences-$0.22-$0.29-$0.07-$0.29N/AN/A8/6/2025Q2 2025VRDNViridian Therapeutics-$1.00-$1.00N/A-$1.00$0.05 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ASBMProShares Short Basic Materials$0.070.15%N/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85OKYOOKYO PharmaN/A0.400.40PMNPromis NeurosciencesN/A0.970.97SBMProShares Short Basic MaterialsN/AN/AN/AVRDNViridian Therapeutics0.0411.0111.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%OKYOOKYO Pharma2.97%PMNPromis Neurosciences50.13%SBMProShares Short Basic MaterialsN/AVRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics7.30%OKYOOKYO Pharma40.46%PMNPromis Neurosciences3.80%SBMProShares Short Basic MaterialsN/AVRDNViridian Therapeutics0.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.52 million66.18 millionNot OptionableOKYOOKYO Pharma737.61 million22.39 millionNot OptionablePMNPromis Neurosciences553.81 million51.77 millionNot OptionableSBMProShares Short Basic MaterialsN/A40,000N/ANot OptionableVRDNViridian Therapeutics5081.67 million81.14 millionOptionableVRDN, SBM, IKT, PMN, and OKYO HeadlinesRecent News About These CompaniesViridian Therapeutics in Royalty Financing Deal With DRI Healthcare for Up to $300MOctober 20 at 11:25 AM | marketwatch.comViridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 MillionOctober 20 at 7:30 AM | businesswire.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $34.88 Consensus Price Target from AnalystsOctober 20 at 3:09 AM | americanbankingnews.comStifel Nicolaus Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)October 19 at 4:24 AM | theglobeandmail.comViridian Therapeutics (NASDAQ:VRDN) Trading 3.9% Higher - What's Next?October 18 at 12:45 PM | marketbeat.comUnderwhelming Roche data helps Veridian’s position in TED, says JefferiesOctober 17 at 7:06 PM | msn.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 15, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Viridian Therapeutics (NASDAQ:VRDN)October 9, 2025 | marketbeat.comViridian Therapeutics, Inc. $VRDN Shares Acquired by J. Safra Sarasin Holding AGOctober 4, 2025 | marketbeat.comViridian Therapeutics: De-Risked Leadership In Thyroid Eye DiseaseSeptember 26, 2025 | seekingalpha.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 20, 2025 | marketbeat.comViridian Therapeutics Completes Enrollment in Phase III Trial for Novel Monoclonal Antibody in Thyroid Eye DiseaseSeptember 19, 2025 | appliedclinicaltrialsonline.comAViridian Therapeutics completes patient enrollment in REVEAL-1 & REVEAL-2 phase 3 trials of VRDN-003 to treat active and chronic TEDSeptember 16, 2025 | pharmabiz.comPViridian Therapeutics completes enrollment in REVEAL-1, REVEAL-2 studiesSeptember 15, 2025 | msn.comViridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio UpdatesSeptember 15, 2025 | businesswire.comViridian Therapeutics files automatic mixed securities shelfSeptember 6, 2025 | msn.comThese Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 ResultsAugust 7, 2025 | benzinga.comViridian partners with Kissei Pharmaceutical to develop thyroid eye disease therapies in JapanAugust 7, 2025 | ophthalmologytimes.comOViridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue EstimatesAugust 6, 2025 | zacks.comViridian Therapeutics and Kissei Pharmaceutical Enter $70 Million Collaboration and License Agreement to Develop Veligrotug & VRDN-003August 1, 2025 | pharmexec.comPNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught?By Leo Miller | October 3, 2025VRDN, SBM, IKT, PMN, and OKYO Company DescriptionsInhibikase Therapeutics NYSE:IKT$1.62 +0.05 (+3.18%) Closing price 04:00 PM EasternExtended Trading$1.62 0.00 (0.00%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.OKYO Pharma NASDAQ:OKYO$2.43 +0.19 (+8.48%) Closing price 04:00 PM EasternExtended Trading$2.41 -0.02 (-0.82%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Promis Neurosciences NASDAQ:PMN$0.45 +0.01 (+2.81%) Closing price 04:00 PM EasternExtended Trading$0.45 +0.00 (+0.02%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.ProShares Short Basic Materials NYSEARCA:SBM$46.38 0.00 (0.00%) As of 10/17/2025ProShares Short Basic Materials (the Fund) seeks daily investment results that correspond to the inverse (opposite) of the daily performance of Dow Jones U.S. Basic Materials Index (the Index). The Index measures the performance of the basic materials industry of the United States equity market. The Fund invests in derivatives as a substitute for directly shorting stocks in order to gain inverse exposure to the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. The Fund also invests in short-term cash instruments that have terms to maturity of less than 397 days and exhibit credit profiles. ProShare Advisors LLC is the investment advisor of the Fund.Viridian Therapeutics NASDAQ:VRDN$24.09 -0.12 (-0.50%) Closing price 04:00 PM EasternExtended Trading$24.08 0.00 (-0.02%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
